FDA
-
-
-
-
-
-
-
Concert Pharma (CNCE) Reports Presentation of CTP-543 THRIVE-AA1 Phase 3 Data
-
-
-
-
-
-
-
Concert Pharma (CNCE) Reports Publication of Phase 2 Dose‑Ranging Trial Results of CTP‑543
-
-
-
-
-
-
-
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
-
-
-
-
-
-
-
Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
-
-
-
-
-
-
-
Concert Pharma (CNCE) Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
-
-
-
-
-
-
-
Concert Pharma (CNCE) Announces Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata
-
-
-
-
-
-
-
Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting
-
251,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All